Related Experiment Video
Updated: May 25, 2026
Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
Published on: May 13, 2021
ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS
J Carson1, D Haddad, M Bressman
1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Abstract:
Viruses have long been considered potential anticancer treatments. Wild-type viruses have been tested as anticancer agents in clinical trials since the 1960s. The possibility of viral oncolysis as an alternate cancer therapy was transformed by the emergence of modern genetic engineering. The herpes simplex virus (HSV) family offers particular advantages for use as a viral oncolytic. The engineered vectors that make up oncolytic HSVs (oHSVs) have demonstrated remarkable safety in clinical trials, with some evidence of efficacy. The past decade has seen a focus on increasing the efficacy of oncolytic vectors by adding exogenous transgenes to enhance tumor destruction. The current paper describes the various strategies for engineering HSV for increased cancer tissue specificity and efficacy. Presented are the rationale, preclinical data and clinical data where available. This is meant to illustrate a basic framework for the development of a novel therapy meant to exploit the viral life cycle for the killing of cancer.
Insights
Genetic engineering transforms herpes simplex virus (HSV) into oncolytic HSVs (oHSVs) for cancer therapy. These engineered viruses show promise for targeted tumor destruction and enhanced efficacy in clinical trials.
Area of Science:
- Oncolytic virotherapy
- Cancer gene therapy
- Viral oncology
Background:
- Viruses have been explored as anticancer agents since the 1960s.
- Genetic engineering has advanced the potential of viral oncolysis as an alternative cancer therapy.
- Herpes simplex virus (HSV) is a promising candidate for viral oncolytic development.
Purpose of the Study:
- To describe strategies for engineering HSV to improve cancer tissue specificity and efficacy.
- To present the rationale, preclinical, and clinical data for engineered oncolytic HSVs (oHSVs).
- To illustrate a framework for developing novel therapies that utilize the viral life cycle for cancer cell killing.
Main Methods:
- Engineering of HSV vectors to create oncolytic HSVs (oHSVs).
- Introduction of exogenous transgenes into oHSVs to enhance tumor destruction.
- Review of preclinical and clinical data for engineered oHSVs.
Main Results:
- Engineered oHSVs have demonstrated notable safety in clinical trials.
- Evidence suggests efficacy of oHSVs in targeting and destroying cancer cells.
- Strategies focus on enhancing tumor-specific targeting and therapeutic effect.
Conclusions:
- Engineered HSV vectors offer a promising platform for oncolytic virotherapy.
- Further development focuses on increasing specificity and efficacy through genetic modification.
- oHSVs represent a novel therapeutic approach exploiting viral mechanisms for cancer treatment.
